drugset
drugset / Trial / NCT00429039

A Study to Accelerate Immune System Recovery Following Stem Cell Transplantation

NCT00429039 ↗

Phase 2 Terminated 21 enrolled Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if pre-treating donor lymphocytes with an investigational drug known as L-leucyl-L-leucine methyl ester (LLME, prior to donor lymphocyte infusion (DLI) will improve the recovery of the immune system following stem cell transplant.

Timeline

Start
2000-09
Primary completion
2007-10
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject L-leucyl-L-leucine Methyl Ester Unknown — —

Indications

disease related to hematopoietic stem cell transplant